Botanix Pharmaceuticals Limited (AU:BOT)
ASX:BOT
Want to see AU:BOT full AI Analyst Report?
BOT Stock Chart & Stats
AU$0.04
>-AU$0.01(-1.09%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-1.09%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.36
Previous CloseN/A
Volume8.15M
Average Volume (3M)8.47M
Market Cap
AU$60.15M
Enterprise ValueAU$46.88M
Total Cash (Recent Filing)AU$31.61M
Total Debt (Recent Filing)AU$30.67M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 28, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding2,734,312,700
10 Day Avg. Volume7,344,780
30 Day Avg. Volume8,473,310
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.26
Price to Sales (P/S)101.98
P/FCF Ratio-7.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.57Price Target Upside1325.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$34.99M
Bulls Say, Bears Say
Bulls Say
Rapid Prescription And Revenue GrowthSustained, steep prescription and net‑revenue ramp signals clear product‑market fit and accelerating commercial adoption. Durable volume growth can underpin scalable unit economics, support payer coverage expansion and justify continued commercial investment as revenue growth outpaces fixed costs over time.
High-performing SendRx Fulfillment PlatformA best‑in‑class fulfillment platform raises barriers to entry and materially improves gross‑to‑net conversion, reimbursement and adherence. Its scalability across products reduces marginal go‑to‑market costs, bolsters payer/provider relationships and supports sustainable revenue and margin expansion over multiple product launches.
Strong IP Runway And Large Addressable MarketLong patent protection and a multi‑million patient TAM provide a durable commercial runway and strategic optionality. IP exclusivity supports pricing leverage, potential M&A interest and extended ROI on commercialization spend, enabling multi‑year revenue generation if adoption and payer coverage persist.
Bears Say
Large Operating Losses And Cash BurnMaterial negative operating cash flow and sizeable losses create persistent financing need and dilution risk unless margins or external funding improve. High burn limits strategic optionality, pressures timing of manufacturing and marketing scale‑up, and makes execution dependent on securing further capital.
Single‑source API And Near‑term Purchase ObligationsConcentration on one API supplier creates operational and price risk; scheduled purchase obligations can strain cashflow. Delays or disruptions would impair supply continuity and revenues. Qualifying an alternate supplier is costly and time‑consuming, making this a persistent execution vulnerability.
Capital Raise Partially Funded And ContingentDependence on a contingent $45M raise leaves the company exposed to approval and market execution risk. Failure or delay could force hurried or dilutive financing, reduce funding for alternate API qualification and marketing, and constrain the company's ability to convert commercial momentum into sustained profitability.
Botanix Pharmaceuticals Limited News
BOT FAQ
What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?
Botanix Pharmaceuticals Limited lowest share price was AU$0.02 and its highest was AU$0.36 in the past 12 months.
What is Botanix Pharmaceuticals Limited’s market cap?
Botanix Pharmaceuticals Limited’s market cap is AU$60.15M.
When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?
Botanix Pharmaceuticals Limited’s upcoming earnings report date is Aug 28, 2026 which is in 82 days.
How were Botanix Pharmaceuticals Limited’s earnings last quarter?
Botanix Pharmaceuticals Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.007.
Is Botanix Pharmaceuticals Limited overvalued?
According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued.
Does Botanix Pharmaceuticals Limited pay dividends?
Botanix Pharmaceuticals Limited does not currently pay dividends.
What is Botanix Pharmaceuticals Limited’s EPS estimate?
Botanix Pharmaceuticals Limited’s EPS estimate is -0.01.
How many shares outstanding does Botanix Pharmaceuticals Limited have?
Botanix Pharmaceuticals Limited has 2,734,312,700 shares outstanding.
What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?
Botanix Pharmaceuticals Limited reported an EPS of -AU$0.017 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:BOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Botanix Pharmaceuticals Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.57 (1325.00% Upside)
AU$0.57 (1325.00% Upside)
Blogger Sentiment
Bullish
AU:BOT Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$450.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.57%
12-Months-Change
Fundamentals
Return on Equity
-131.13%
Trailing 12-Months
Asset Growth
-0.88%
Trailing 12-Months
Company Description
Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
BOT Stock 12 Month Forecast
Average Price Target
AU$0.57
▲(1325.00% Upside)
Technical Analysis
Options Prices
Currently, No data available
---